Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib + HAM in R/R AML with FLT3-ITD
NCT03989713Phase 2Terminated
- Start
- Jul 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of quizartinib in acute myeloid leukemia (AML). Primary endpoint: Composite Remission Rate at 100 days. Started Jul 2020; status: terminated.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03989713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989713.